Immunohistochemical Examination of Anti-STn Monoclonal Antibodies LLU9B4, B72.3, and B35.2 for Their Potential use as Tumor Markers

2008 ◽  
Vol 53 (8) ◽  
pp. 2189-2194 ◽  
Author(s):  
Keshab D. Pant ◽  
Ankur Jain ◽  
John D. McCracken ◽  
Kevin Thompson
Keyword(s):  
Monoclonal Antibodies ◽  
Tumor Markers ◽  
Immunohistochemical Examination ◽  
Potential Use

scholarly journals Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab

2021 ◽  
Vol 14 (8) ◽  
pp. e243469
Author(s):  
Carlos X Rabascall ◽  
Becky X Lou ◽  
Brianne Navetta-Modrov ◽  
Stella S Hahn
Keyword(s):  
Monoclonal Antibodies ◽  
Symptom Onset ◽  
Severe Disease ◽  
Therapeutic Window ◽  
Immunosuppressed Patient ◽  
Unique Case ◽  
Risk Of Progression ◽  
Immunosuppressed Patients ◽  
Effective Use ◽  
Potential Use

As we are over a year into the COVID-19 pandemic, we have made many forward strides in therapeutics. These treatments, such as monoclonal antibodies, have help mitigate the detrimental and often fatal consequences of COVID-19. The current indication for the use of monoclonal antibodies is mild to moderate COVID-19 infection within 10 days of symptom onset in those who are at high risk of progression to severe disease. However, their role in patients with prolonged symptoms is not clear. We present a unique case of monoclonal antibodies use after 54 days of symptom onset in an immunosuppressed patient with persistent COVID-19 infection despite standard treatment. This case illustrates the potential use of monoclonal antibodies outside of the current recommended therapeutic window in immunosuppressed patients, who may have difficulty with viral clearance.

Monoclonal Antibodies Against Human Germ Cell Tumors: Usefulness as Tumor Markers and Differentiation Markers

1987 ◽  
Vol 29 (4) ◽  
pp. 557-560
Author(s):  
Jun-ichi Hata ◽  
Junichiro Fujimoto ◽  
Eizaburo Ishii ◽  
Shigeki Tanaka
Keyword(s):  
Monoclonal Antibodies ◽  
Germ Cell ◽  
Tumor Markers ◽  
Germ Cell Tumors ◽  
Differentiation Markers

Abstract 2857: Monoclonal antibodies against novel tumor markers for cancer diagnosis and treatment .

2013 ◽  
Author(s):  
Renata Maria Grifantini ◽  
Piero Pileri ◽  
Matteo Parri ◽  
Alberto Grandi ◽  
Susanna Campagnoli ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Tumor Markers ◽  
Cancer Diagnosis ◽  
Diagnosis And Treatment

scholarly journals Monoclonal antibodies directed against the flagella ofCampylobacter jejuni: cross-reacting and serotypic specificity and potential use in diagnosis

1986 ◽  
Vol 96 (3) ◽  
pp. 377-384 ◽  
Author(s):  
D. G. Newell
Keyword(s):  
Monoclonal Antibody ◽  
Monoclonal Antibodies ◽  
Campylobacter Jejuni ◽  
Clinical Material ◽  
Faecal Material ◽  
Ofcampylobacter Jejuni ◽  
Elisa Technique ◽  
Flagellar Antigen ◽  
Potential Use

SUMMARYNine monoclonal antibodies directed against the flagella ofCampylobacter jejunistrain 81116 have been investigated for serotypic and cross-reacting activity using a panel of 17 Penner serotype strains ofC. jejuni.Four monoclonal antibodies were exclusively specific for serotype-6 strains, which was the serotype ofC. jejunistrain 81116. Two monoclonal antibodies cross-reacted with all the flagellated strains ofC jejunitested. One of these cross-reacting monoclonal antibodies, CF5, was found to react with all otherCampylobacterspecies exceptC. sputorum bulbulusbut it did not react with other bacterial entcropathogens. An antigencapture ELISA technique was established, using this monoclonal antibody, which could detect flagellar antigen in human faecal material. These anti-flagella monoclonal antibodies therefore may be valuable in the diagnosis and serotyping ofC. jejuniin clinical material.

scholarly journals Generation and characterization of monoclonal antibodies against choline kinase α and their potential use as diagnostic tools in cancer

2006 ◽  
Author(s):  
David Gallego-Ortega ◽  
Ana Ramirez De Molina ◽  
Ruth Gutierrez ◽  
Maria Ramos ◽  
Jacinto Sarmentero ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Diagnostic Tools ◽  
Choline Kinase ◽  
Potential Use

scholarly journals Generation and Characterization of Anti-phenyl Sulfate Monoclonal Antibodies and a Potential Use for Phenyl Sulfate Analysis in Human Blood

2018 ◽  
Vol 41 (8) ◽  
pp. 1170-1177
Author(s):  
Yoshitomi Kanemitsu ◽  
Hiroki Tsukamoto ◽  
Yotaro Matsumoto ◽  
Kanako Nozawa-Kumada ◽  
Yoshinori Kondo ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Human Blood ◽  
Potential Use

scholarly journals The use of oligonucleotide probes for meningococcal serotype characterization

1998 ◽  
Vol 40 (2) ◽  
pp. 113-117 ◽  
Author(s):  
Claudio Tavares SACCHI ◽  
Ana Paula Silva de LEMOS ◽  
Anne M. Whitney ◽  
Carmo Elias A. MELLES ◽  
Claude André SOLARI ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Neisseria Meningitidis ◽  
Rapid Method ◽  
Gene Sequence ◽  
Prototype Strain ◽  
Oligonucleotide Probes ◽  
Type B ◽  
Variable Regions ◽  
Antigenic Diversity ◽  
Potential Use

In the present study we examine the potential use of oligonucleotide probes to characterize Neisseria meningitidis serotypes without the use of monoclonal antibodies (MAbs). Antigenic diversity on PorB protein forms the bases of serotyping method. However, the current panel of MAbs underestimated, by at least 50% the PorB variability, presumably because reagents for several PorB variable regions (VRs) are lacking, or because a number of VR variants are not recognized by serotype-defining MAbs12. We analyzed the use of oligonucleotide probes to characterize serotype 10 and serotype 19 of N. meningitidis. The porB gene sequence for the prototype strain of serotype 10 was determined, aligned with 7 other porB sequences from different serotypes, and analysis of individual VRs were performed. The results of DNA probes 21U (VR1-A) and 615U (VR3-B) used against 72 N. meningitidis strains confirm that VR1 type A and VR3 type B encode epitopes for serotype-defined MAbs 19 and 10, respectively. The use of probes for characterizing serotypes possible can type 100% of the PorB VR diversity. It is a simple and rapid method specially useful for analysis of large number of samples.

scholarly journals Direct Administration in the Respiratory Tract Improves Efficacy of Broadly Neutralizing Anti-Influenza Virus Monoclonal Antibodies

2015 ◽  
Vol 59 (7) ◽  
pp. 4162-4172 ◽  
Author(s):  
Victor H. Leyva-Grado ◽  
Gene S. Tan ◽  
Paul E. Leon ◽  
Mark Yondola ◽  
Peter Palese
Keyword(s):  
Influenza Virus ◽  
Monoclonal Antibodies ◽  
Therapeutic Agent ◽  
Influenza Infection ◽  
Virus Challenge ◽  
Routes Of Administration ◽  
Neutralizing Monoclonal Antibody ◽  
Direct Administration ◽  
Virus Strains ◽  
Potential Use

ABSTRACTThe emergence of influenza virus strains resistant to approved neuraminidase inhibitors and the time constrains after infection when these drugs can be effective constitute major drawbacks for this class of drugs. This highlights a critical need to discover new therapeutic agents that can be used for the treatment of influenza virus-infected patients. The use of broadly neutralizing anti-influenza monoclonal antibodies (MAbs) has been sought as an alternative immunotherapy against influenza infection. Here, we tested in mice previously characterized broadly neutralizing anti-hemagglutinin (HA) stalk MAbs prophylactically and therapeutically using different routes of administration. The efficacy of treatment against an influenza H1N1 pandemic virus challenge was compared between two systemic routes of administration, intraperitoneal (i.p.) and intravenous (i.v.), and two local routes, intranasal (i.n.) and aerosol (a.e.). The dose of MAb required for prophylactic protection was reduced by 10-fold in animals treated locally (i.n. or a.e.) compared with those treated systemically (i.p. or i.v.). Improved therapeutic protection was observed in animals treated i.n. on day 5 postinfection (60% survival) compared with those treated via the i.p. route (20% survival). An increase in therapeutic efficacy against other influenza virus subtypes (H5N1) was also observed when a local route of administration was used. Our findings demonstrate that local administration significantly decreases the amount of broadly neutralizing monoclonal antibody required for protection against influenza, which highlights the potential use of MAbs as a therapeutic agent for influenza-associated disease.

Sign in / Sign up

Export Citation Format

Share Document